[go: up one dir, main page]

ATE119777T1 - Behandlungsmethoden für osteoporose. - Google Patents

Behandlungsmethoden für osteoporose.

Info

Publication number
ATE119777T1
ATE119777T1 AT92908494T AT92908494T ATE119777T1 AT E119777 T1 ATE119777 T1 AT E119777T1 AT 92908494 T AT92908494 T AT 92908494T AT 92908494 T AT92908494 T AT 92908494T AT E119777 T1 ATE119777 T1 AT E119777T1
Authority
AT
Austria
Prior art keywords
osteoporosis
treatment
treatment methods
subject
phosphonate
Prior art date
Application number
AT92908494T
Other languages
English (en)
Inventor
Jocelyn Elaine Mcosker
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Application granted granted Critical
Publication of ATE119777T1 publication Critical patent/ATE119777T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Removal Of Specific Substances (AREA)
AT92908494T 1991-02-26 1992-01-31 Behandlungsmethoden für osteoporose. ATE119777T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66177791A 1991-02-26 1991-02-26

Publications (1)

Publication Number Publication Date
ATE119777T1 true ATE119777T1 (de) 1995-04-15

Family

ID=24655074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92908494T ATE119777T1 (de) 1991-02-26 1992-01-31 Behandlungsmethoden für osteoporose.

Country Status (18)

Country Link
US (1) US6329354B1 (de)
EP (1) EP0573604B1 (de)
JP (1) JP3727332B2 (de)
KR (1) KR100240358B1 (de)
AT (1) ATE119777T1 (de)
AU (1) AU664368B2 (de)
CA (1) CA2101275C (de)
CZ (1) CZ282609B6 (de)
DE (1) DE69201725T2 (de)
DK (1) DK0573604T3 (de)
ES (1) ES2069424T3 (de)
HU (1) HU215124B (de)
IE (1) IE65963B1 (de)
NO (1) NO305581B1 (de)
NZ (1) NZ241717A (de)
RU (1) RU2113848C1 (de)
SK (1) SK90093A3 (de)
WO (1) WO1992014474A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07504672A (ja) * 1992-03-21 1995-05-25 エンテック　ゲゼルシャフト　フュア　エンドクリノロギッシェ　テヒノロギー　エム．ベー．ハー． 更年期骨粗鬆症の処置に対するエストリオールの使用
US5635495A (en) * 1992-10-09 1997-06-03 The Upjohn Company Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
JPH08505142A (ja) * 1992-12-23 1996-06-04 メルク エンド カンパニー インコーポレーテッド 骨損失を治療及び予防するためのビスホスホネート／エストロゲン療法
ATE128363T1 (de) * 1993-05-15 1995-10-15 Boehringer Mannheim Gmbh Tablette mit verbesserter bioverfügbarkeit enthaltend dichlormethylendiphosphonsäure als wirkstoff.
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
CA2208714C (en) * 1994-12-28 2003-10-21 Gador S.A. Bone mass anabolic composition comprising olpadronate
DE19635883A1 (de) * 1996-09-04 1998-03-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
WO1998023274A1 (en) * 1996-11-25 1998-06-04 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
CN1217666C (zh) * 1998-12-25 2005-09-07 东丽株式会社 白介素－6产生抑制剂
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US6653298B2 (en) 2000-01-14 2003-11-25 Sterix Limited Composition
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
EP2225252B1 (de) * 2007-11-30 2012-06-27 Novartis AG C2-c5-alkylimidazolbisphosphonate
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553314A (en) 1968-12-23 1971-01-05 Procter & Gamble Oral compositions for calculus retardation
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
EP0088462A3 (de) * 1982-03-01 1984-06-06 The Procter & Gamble Company Entzündungshemmende und antirheumatische Zusammensetzung mit Gehalt an einem Organophosphonat und einem Steroiden
DE3583887D1 (de) * 1984-04-30 1991-10-02 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
IL86951A (en) 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
JPH06505501A (ja) 1994-06-23
NO305581B1 (no) 1999-06-28
CA2101275C (en) 1998-08-04
NO933044D0 (no) 1993-08-26
HU215124B (hu) 1998-09-28
HU9302407D0 (en) 1993-11-29
EP0573604A1 (de) 1993-12-15
RU2113848C1 (ru) 1998-06-27
AU664368B2 (en) 1995-11-16
IE920584A1 (en) 1992-08-26
NZ241717A (en) 1997-02-24
US6329354B1 (en) 2001-12-11
HUT66429A (en) 1994-11-28
NO933044L (no) 1993-08-26
KR100240358B1 (ko) 2000-02-01
JP3727332B2 (ja) 2005-12-14
CZ282609B6 (cs) 1997-08-13
CA2101275A1 (en) 1992-08-27
CZ175593A3 (en) 1994-04-13
IE65963B1 (en) 1995-11-29
ES2069424T3 (es) 1995-05-01
WO1992014474A1 (en) 1992-09-03
SK90093A3 (en) 1994-09-07
AU1643392A (en) 1992-09-15
DE69201725T2 (de) 1996-04-18
DK0573604T3 (da) 1995-05-29
DE69201725D1 (de) 1995-04-20
EP0573604B1 (de) 1995-03-15

Similar Documents

Publication Publication Date Title
DE69201725D1 (de) Behandlungsmethoden für osteoporose.
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ES2179473T3 (es) Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local.
PT850068E (pt) Extracto lipidico com actividade anti-inflamatoria
ES2133413T3 (es) Gel de lecitina inyectable.
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
NO942241L (de)
ATE152627T1 (de) Verfahren zur anregung der immunresponz
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
ES2114851T3 (es) Utilizacion de composiciones de liberacion sostenida que contienen gnrh, lhrh o derivados de las mismas.
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
ES2089177T3 (es) Nuevos peptidos inhibidores.
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
BR9810884A (pt) Uso de uma preparação de lipìdeo derivada de uma fonte natural enriquecida
ATE81972T1 (de) Zusammensetzungen und verfahren zur behandlung von magengeschwueren.
DE69220229D1 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder
MX9206339A (es) Nueva proteina inhibidora de trombina a partir de chinches de monte
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee